BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 7, 2026
Breaking News: BioWorld Science 2025 Year in Review
See today's BioWorld Science
Home
» UP Oncolytics’ oncolytic virus-based therapy awarded US orphan drug designation to treat malignant glioma
To read the full story,
subscribe
or
sign in
.
Cancer
UP Oncolytics’ oncolytic virus-based therapy awarded US orphan drug designation to treat malignant glioma
Oct. 24, 2024
The FDA has awarded orphan drug designation to UP Oncolytics LLC’s oncolytic virus-based therapy (ZIKV-SJRP/2016) to treat malignant glioma.
BioWorld Science
Regulatory
Cancer
FDA
Orphan drug